Hospira Symbiq Infusion System Touchscreen: Class 1 Recall – May Not Respond to Selection

by FDA on October 29, 2012

in MedWatch

Failure of touchscreen to respond to user input could result in a delay or interruption in therapy or over delivery or under delivery of medication.

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Leave a Comment

Previous post:

Next post: